



[Go to Product page](#)

Datasheet for ABIN6256779  
**anti-PKC delta antibody (pTyr64)**

3 Images

### Overview

Quantity:	100 µL
Target:	PKC delta (PKCd)
Binding Specificity:	pTyr64
Reactivity:	Human, Mouse, Rat
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This PKC delta antibody is un-conjugated
Application:	Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)

### Product Details

Immunogen:	A synthesized peptide derived from human PKC delta around the phosphorylation site of Tyr64.
Isotype:	IgG
Specificity:	Phospho-PKC delta (Tyr64) Antibody detects endogenous levels of PKC delta only when phosphorylated at Tyrosine 64.
Predicted Reactivity:	Pig,Bovine,Horse,Sheep,Rabbit,Dog,Chicken,Xenopus
Purification:	The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns.

### Target Details

Target:	PKC delta (PKCd)
---------	------------------

## Target Details

---

Alternative Name: PRKCD ([PKCd Products](#))

---

**Background:** Description: Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses. Negatively regulates B cell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage, activates the promoter of the death-promoting transcription factor BCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcription and apoptosis. In response to oxidative stress, interact with and activate CHUK/IKKA in the nucleus, causing the phosphorylation of p53/TP53. In the case of ER stress or DNA damage-induced apoptosis, can form a complex with the tyrosine-protein kinase ABL1 which trigger apoptosis independently of p53/TP53. In cytosol can trigger apoptosis by activating MAPK11 or MAPK14, inhibiting AKT1 and decreasing the level of X-linked inhibitor of apoptosis protein (XIAP), whereas in nucleus induces apoptosis via the activation of MAPK8 or MAPK9. Upon ionizing radiation treatment, is required for the activation of the apoptosis regulators BAX and BAK, which trigger the mitochondrial cell death pathway. Can phosphorylate MCL1 and target it for degradation which is sufficient to trigger for BAX activation and apoptosis. Is required for the control of cell cycle progression both at G1/S and G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclin CCNA2 promoter activity. In response to UV irradiation can phosphorylate CDK1, which is important for the G2/M DNA damage checkpoint activation. Can protect glioma cells from the apoptosis induced by TNFSF10/TRAIL, probably by inducing increased phosphorylation and subsequent activation of AKT1. Is highly expressed in a number of cancer cells and promotes cell survival and resistance against chemotherapeutic drugs by inducing cyclin D1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3 (ERK1/2). Can also act as tumor suppressor upon mitogenic stimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity, and regulates TNF-elicited superoxide anion production in neutrophils, by direct phosphorylation and activation of NCF1 or indirectly through MAPK1/3 (ERK1/2) signaling pathways. May also play a role in the regulation of NADPH oxidase activity in eosinophil after stimulation with IL5, leukotriene B4 or PMA. In collagen-induced platelet aggregation, acts a negative regulator of

---

## Target Details

---

filopodia formation and actin polymerization by interacting with and negatively regulating VASP phosphorylation. Downstream of PAR1, PAR4 and CD36/GP4 receptors, regulates differentially platelet dense granule secretion, acts as a positive regulator in PAR-mediated granule secretion, whereas it negatively regulates CD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (By similarity). Phosphorylates ELAVL1 in response to angiotensin-2 treatment (PubMed:18285462).

Gene: PRKCD

---

Molecular Weight: 78kDa

---

Gene ID: 5580

---

UniProt: [Q05655](#)

---

Pathways: [Interferon-gamma Pathway](#), [EGFR Signaling Pathway](#), [Neurotrophin Signaling Pathway](#), [Thyroid Hormone Synthesis](#), [Regulation of Actin Filament Polymerization](#), [Carbohydrate Homeostasis](#), [Myometrial Relaxation and Contraction](#), [M Phase](#), [G-protein mediated Events](#), [Dicarboxylic Acid Transport](#), [Positive Regulation of Response to DNA Damage Stimulus](#), [Interaction of EGFR with phospholipase C-gamma](#), [Thromboxane A2 Receptor Signaling](#), [Lipid Metabolism](#)

## Application Details

---

Application Notes: WB 1:500-1:2000, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000

---

Restrictions: For Research Use only

## Handling

---

Format: Liquid

---

Concentration: 1 mg/mL

---

Buffer: Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

---

Preservative: Sodium azide

---

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

---

Storage: -20 °C


---

## Handling

Storage Comment: Store at -20 °C. Stable for 12 months from date of receipt.


Expiry Date: 12 months

## Images




### Immunofluorescence (fixed cells)

**Image 1.** ABIN6267619 staining NIH-3T3 by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100, then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) Ab, diluted at 1/600, was used as the secondary antibody.



### Western Blotting

**Image 2.** Western blot analysis of PKCD phosphorylation expression in PMA treated HepG2 whole cell lysates, The lane on the left is treated with the antigen-specific peptide.



### Western Blotting

**Image 3.** Western blot analysis of Phospho-PKCD (Tyr64) expression in various lysates